gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SEERHealthcareLab Analytical Instruments

Seer, Inc. Class A Common Stock (SEER)

$1.70−1.73%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.72▼ 24.45% in range
Nov 3, 2025Low $1.62 · High $2.33Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Seer closed at $1.70 on Nov 4, down 1.73%, 27.0% below its 52-week closing high. Volume of 62.8K shares was 0.33× its 20-day average (below normal).

Split-adjusted performance: -22.4% over one month, -10.1% over six months, -25.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $3.10M, down 23.4% from a year earlier, with a net margin of -544.8%.

Short interest was 94.4K shares at the Oct 15 settlement, down 13.1% from the prior report (0.3% of float, 1.0 days to cover).

Market cap$94.1M55.4M shares
Revenue · quarter$3.1M−23.4% YoY
Diluted EPS$-0.31—
P/E · TTM—P/S 6.6×
Net margin-544.8%Gross 48.5%
Dividend yieldNone
52-week range1.62 – 2.33−27.0% from high
Volume62.8K0.33× 20-day avg
Volatility · 60d44.9%Annualised
Short % of float0.3%1.0 days to cover
Net cash$152.9MCash $152.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −14.6%1M −22.4%3M −22.4%6M −10.1%YTD −7.1%1Y −25.1%3Y +0.6%5Y −95.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum20
Revenue growth11
Net margin14
Value (low P/E)—
Size29

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short94.4K−13.1% vs prior
Days to cover1.0Settled Oct 15
% of float0.3%
Short vol. 10d38.8%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1M
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
HBIOHarvard Bioscience$8.61−0.69%+18.9%+11.1%−12.8%—$39.2MCompare
PRPOPrecipio$19.57+5.10%−34.7%+24.7%−3.1%—$35.0MCompare
RPIDRapid Micro Biosystems$0.6814−1.53%−73.1%+10.9%−160.5%—$34.2MCompare
EYPTEyePoint$0.3950−1.23%−97.0%−90.5%−18633.1%—$34.1MCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare
MASS908 Devices$11.07+3.75%+37.3%+23.3%−74.0%—$457.6MCompare
BNGOBionano Genomics$1.19−0.83%−6.3%+21.4%−90.8%—$16.6MCompare

News about Seer

All news →
Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual MeetingGlobeNewswire Inc. · Jul 28, 2026▲ PositiveSeer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation PotentialGlobeNewswire Inc. · Jul 6, 2026▲ PositiveSeer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC GroupGlobeNewswire Inc. · Apr 13, 2026▼ Negative

Quick answers

What does Seer do?
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
What is SEER's market cap?
$94.13M, based on the Nov 4 close of $1.70.
Does Seer pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SEER is sold short?
94.4K shares, 0.3% of float, as of Oct 15, 2026.
What sector is SEER in?
Healthcare, in the Lab Analytical Instruments industry.

About Seer

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

HQ: Redwood City, CA124 employeesListed Dec 4, 2020seer.bio

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology